Methods and compositions for risk prediction, diagnosis, prognosis, and treatment of pulmonary disorders
AssigneeNational Jewish Health
InventorsDavid A. Schwartz, Max Seibold
Life of this patent
Estimating the term…
Abstract
The invention provides diagnostic and therapeutic targets for pulmonary disease, in particular, fibrotic lung disease. The inventors have found that a genetic variant MUC5B gene is associated with increased expression of the gene, increased risk of developing a pulmonary disease, and an improved prognosis and survival among those developing the pulmonary disease.
Claims30
A method of determining whether a subject has or is at risk of developing an interstitial lung disease, said method comprising detecting whether a genome of a subject comprises a genetic variant MUC5B gene, wherein the presence of said genetic variant MUC5B gene indicates said subject has or is at risk of developing a pulmonary disease.
(canceled)
(canceled)
8-11. (canceled)
14-18. (canceled)
20-23. (canceled)
A method of determining whether a subject has or is at risk of developing an interstitial lung disease, said method comprising detecting whether a subject expresses an elevated MUC5B RNA level or an elevated MUC5B protein level relative to a standard control, wherein the presence of said elevated MUC5B RNA level or said elevated MUC5B protein level indicates said subject has or is at risk of developing an interstitial lung disease.
(canceled)
(canceled)
30-33. (canceled)
A method of prognosing an interstitial lung disease in a patient, said method comprising detecting whether a genome of a subject comprises a genetic variant MUC5B gene, wherein the presence of said genetic variant MUC5B gene indicates an attenuated form of said interstitial lung disease in said patient relative to the absence of said genetic variant MUC5B gene.
(canceled)
40-44. (canceled)
47-86. (canceled)
Dependencies are inferred from the claim text.